Meira, D D <br/><br/>
Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells.  [electronic resource] 

 -  British journal of cancer  Sep 2009 
 - 782-91 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/sj.bjc.6605216  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--pharmacology<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Cell Cycle--drug effects<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cetuximab<br/>Cobalt Radioisotopes<br/>Combined Modality Therapy<br/>Enzyme Inhibitors--pharmacology<br/>ErbB Receptors--antagonists & inhibitors<br/>Female<br/>Humans<br/>Kinetics<br/>Mitogen-Activated Protein Kinases--antagonists & inhibitors<br/>Phosphorylation<br/>RNA, Messenger--biosynthesis<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Sensitivity and Specificity<br/>Trastuzumab<br/>Uterine Cervical Neoplasms--drug therapy<br/>Vascular Endothelial Growth Factors--antagonists & inhibitors